Table 1.
Baseline characteristics of patients with type 2 diabetes as divided into poor and good glycemic control
| Poor glycemic control | Good glycemic control | P value | |
|---|---|---|---|
| Number | 23 | 13 | - |
| Age (years) | 59.7 ± 13.2 (31-86) | 64.7 ± 13.2 (41-86) | 0.287 |
| Sex (male:female) | 9:14 | 5:08 | - |
| BMI (kg/m2) | 23.8 ± 2.8 | 21.6 ± 4.5 | 0.516 |
| Duration of diabetes (years) | 6.7 ± 4.3 (1-15) | 5.2 ± 4.3 (1-13.4) | 0.433 |
| Systolic blood pressure (mmHg) | 126.2 ± 18 (100-170) | 134.4 ± 16 (110-150) | 0.251 |
| Diastolic blood pressure (mmHg) | 79.1 ± 8.9 (60-90) | 76.7 ± 7.1 (70-90) | 0.582 |
| HbA1C (%) | 9.2 ± 1.4 (7-12.2) | 6.2 ± 0.5 (5.3-6.6) | < 0.001 |
| FBS (mmol/l) | 8.9 ± 1.8 (5.8-11.8) | 6.7 ± 0.8 (5.6-8.2) | < 0.001 |
| Total cholesterol (mg/dl) | 175.9 ± 31.9 (134-242) | 191.8 ± 42.6 (148-264) | 0.314 |
| LDL cholesterol (mg/dl) | 98.6 ± 25.3 (61-146) | 125 ± 41.9 (76-215) | 0.936 |
| HDL cholesterol (mg/dl) | 51.8 ± 12.8 (35-75) | 48 ± 13.6 (32-73) | 0.977 |
| Triglyceride (mg/dl) | 137.8 ± 70 (54-310) | 218.5 ± 121.5 (100-340) | 0.124 |
| Therapy | |||
| Statin [n (%)] | 15 (65) | 7 (53) | - |
| ACEI/ARB [n (%)] | 4 (17) | 3 (23) | - |
| Aspirin [n (%)] | 1 (4) | 1 (7) | - |
| OHA [n (%)] | 20 (87) | 10 (77) | - |
| Insulin [n (%)] | 1 (4) | 1 (7) | - |
| OHD + Insulin [n (%)] | 2 (8) | - | - |
Data are presented as mean ± SD, percentage or median (interquartile range); ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body-mass index; FBS, fasting blood sugar; HbA1C, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OHA, oral hypoglycemic agent.